Inactive

8/11/2023 - Update - Extend the due date to 8/21/2023 and upload the answers to the questions. See attachment for Q&A. 8/3/2023- Update- This solicitation has been extended to 8/17. Questions are due ... 8/11/2023 - Update - Extend the due date to 8/21/2023 and upload the answers to the questions. See attachment for Q&A. 8/3/2023- Update- This solicitation has been extended to 8/17. Questions are due 8/10/2023, noon EST. As part of Centers for Disease Control and Prevention's (CDC’s) mission of influenza pandemic preparedness and response, the Influenza Division (ID) develops and delivers medical countermeasures. One such medical countermeasure are candidate vaccine viruses (CVVs), which are precursor vaccine products or seeds developed by partners within the World Health Organization (WHO) Global Influenza Surveillance and Responses System (GISRS). GISRS monitors human influenza disease burden, monitors antigenic drift and other changes (such as antiviral drug resistance) in seasonal influenza viruses, obtains suitable virus isolates for updating of influenza vaccines, and detects and obtains isolates of new influenza viruses infecting humans, especially those with pandemic potential to be use for research and vaccine development. To facilitate the development of the CVVs, CDC uses oligonucleotides and synthetic genes to transcribe the influenza genes to produce the CVVs. ID requires plasmids and linear DNA to be developed routinely based on the constant changes in the genetic make-up of the circulating and novel viruses. These changes are unpredictable and cannot be identified until the viruses are isolated from patients or infected animals. Further, the synthesis of genes is often the rate limiting step in rapid reverse genetics (RG) CVV production, which is required to meet vaccine preparedness goals. Inquiries should be received at the Contracting Office no later than 21 July 2023, submitted via e-mail. See Section 4 (Inquiries) for specific instructions.